Gjalt Huisman, VP Biotherapeutics will be participating in the “PKU Therapies and Development” panel on July 8, 2018 and Kristen Skvorak will be presenting a poster titled, “Development of a protease-stable Phenylalanine Ammonia Lyase (CDX-6114) as an orally-administered enzyme therapy for potential treatment for PKU”.